Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.

Phan YHL, De Abreu Lourenco R, Haas M, van der Linden N.

Mult Scler Relat Disord. 2018 Oct;25:144-149. doi: 10.1016/j.msard.2018.07.020. Epub 2018 Aug 1.

PMID:
30077086
2.

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials.

Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G.

Medicines (Basel). 2018 Jun 21;5(3). pii: E59. doi: 10.3390/medicines5030059.

3.

Cannabinoids for Treatment of MS Symptoms: State of the Evidence.

Rice J, Cameron M.

Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x. Review.

PMID:
29923025
4.

Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.

Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C.

Int J Neurosci. 2018 Sep 13:1-10. doi: 10.1080/00207454.2018.1481066. [Epub ahead of print]

PMID:
29792372
5.

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

Celius EG, Vila C.

Brain Behav. 2018 Apr 6;8(5):e00962. doi: 10.1002/brb3.962. eCollection 2018 May.

6.

Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.

Sorosina M, Clarelli F, Ferrè L, Osiceanu AM, Unal NT, Mascia E, Martinelli V, Comi G, Benigni F, Esposito F, Martinelli Boneschi F.

Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16.

PMID:
29528549
7.

The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.

Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M.

Curr Neurol Neurosci Rep. 2018 Feb 13;18(2):8. doi: 10.1007/s11910-018-0814-x. Review.

PMID:
29442178
8.

The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.

Russo M, Dattola V, Logiudice AL, Ciurleo R, Sessa E, De Luca R, Bramanti P, Bramanti A, Naro A, Calabrò RS.

Medicine (Baltimore). 2017 Nov;96(46):e8826. doi: 10.1097/MD.0000000000008826.

9.

Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.

Giacoppo S, Bramanti P, Mazzon E.

Mult Scler Relat Disord. 2017 Oct;17:22-31. doi: 10.1016/j.msard.2017.06.015. Epub 2017 Jun 27. Review.

PMID:
29055461
10.

THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.

Maniscalco GT, Aponte R, Bruzzese D, Guarcello G, Manzo V, Napolitano M, Moreggia O, Chiariello F, Florio C.

Neurol Sci. 2018 Jan;39(1):97-102. doi: 10.1007/s10072-017-3148-6. Epub 2017 Oct 19.

PMID:
29052091
11.

Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis.

Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, Simes J, Stockler M, Morton RL.

Pharmacoeconomics. 2018 Jan;36(1):67-78. doi: 10.1007/s40273-017-0565-6. Review.

PMID:
28866778
12.

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).

Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, Gasperini C, Zaffaroni M, Petrucci L, Signoriello E, Maniscalco GT, Spinicci G, Matta M, Mirabella M, Pedà G, Castelli L, Rovaris M, Sessa E, Spitaleri D, Paolicelli D, Granata A, Zappia M, Patti F; SA.FE. study group.

PLoS One. 2017 Aug 1;12(8):e0180651. doi: 10.1371/journal.pone.0180651. eCollection 2017.

13.

Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.

Santoro M, Mirabella M, De Fino C, Bianco A, Lucchini M, Losavio F, Sabino A, Nociti V.

J Neurol Sci. 2017 Aug 15;379:298-303. doi: 10.1016/j.jns.2017.06.017. Epub 2017 Jun 15.

PMID:
28716266
14.

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.

Keating GM.

Drugs. 2017 Apr;77(5):563-574. doi: 10.1007/s40265-017-0720-6. Review.

PMID:
28293911
15.

Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D.

Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi: 10.1080/17512433.2017.1292849. Epub 2017 Feb 28. Review.

PMID:
28276775
16.

Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey.

Crowley D, Collins C, Delargy I, Laird E, Van Hout MC.

Harm Reduct J. 2017 Jan 13;14(1):4. doi: 10.1186/s12954-016-0129-7.

17.

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray.

Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S.

Ther Clin Risk Manag. 2016 Nov 11;12:1667-1675. eCollection 2016.

18.

What is new in multiple sclerosis spasticity research? Poster session highlights.

Ghezzi A.

Neurodegener Dis Manag. 2016 Dec;6(6s):45-47.

PMID:
27874498
19.

Country breakout session highlights.

Ghezzi A, Filli L, Solaro C, Mekies C, Landete L, Lycke J.

Neurodegener Dis Manag. 2016 Dec;6(6s):41-44.

PMID:
27874497
20.

Evolution of multiple sclerosis spasticity-associated symptoms: latest data.

Flachenecker P.

Neurodegener Dis Manag. 2016 Dec;6(6s):9-12. Review.

PMID:
27874495

Supplemental Content

Loading ...
Support Center